Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Ferencz, B; Török, K; Pipek, O; Fillinger, J; Csende, K; Lantos, A; Černeková, R; Mitták, M; Škarda, J; Delongová, P; Megyesfalvi, E; Schelch, K; Lang, C; Solta, A; Boettiger, K; Brcic, L; Lindenmann, J; Rényi-Vámos, F; Aigner, C; Berta, J; Megyesfalvi, Z; Döme, B.
Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Cancer Immunol Immunother. 2024; 73(6): 114 Doi: 10.1007/s00262-024-03704-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Brcic Luka
Lindenmann Jörg
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy targets in intermediate- and high-grade LNENs. METHODS: The expressions of V-domain Ig suppressor of T cell activation (VISTA), OX40L, Glucocorticoid-induced TNF receptor (GITR), and T cell immunoglobulin and mucin domain 3 (TIM3) proteins were measured by immunohistochemistry in surgically resected tumor samples of 26 atypical carcinoid (AC), 49 large cell neuroendocrine lung cancer (LCNEC), and 66 small cell lung cancer (SCLC) patients. Tumor and immune cells were separately scored. RESULTS: Tumor cell TIM3 expression was the highest in ACs (p < 0.001), whereas elevated tumor cell GITR levels were characteristic for both ACs and SCLCs (p < 0.001 and p = 0.011, respectively). OX40L expression of tumor cells was considerably lower in ACs (vs. SCLCs; p < 0.001). Tumor cell VISTA expression was consistently low in LNENs, with no significant differences across histological subtypes. ACs were the least immunogenic tumors concerning immune cell abundance (p < 0.001). Immune cell VISTA and GITR expressions were also significantly lower in these intermediate-grade malignancies than in SCLCs or in LCNECs. Immune cell TIM3 and GITR expressions were associated with borderline prognostic significance in our multivariate model (p = 0.057 and p = 0.071, respectively). CONCLUSIONS: LNEN subtypes have characteristic and widely divergent VISTA, OX40L, GITR, and TIM3 protein expressions. By shedding light on the different expression patterns of these immunotherapy targets, the current multicenter study provides support for the future implementation of novel immunotherapeutic approaches.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Lung Neoplasms - immunology, pathology, therapy, metabolism
Male - administration & dosage
Female - administration & dosage
Hepatitis A Virus Cellular Receptor 2 - metabolism
Immunotherapy - methods
Neuroendocrine Tumors - immunology, metabolism, therapy, pathology
Middle Aged - administration & dosage
Aged - administration & dosage
Glucocorticoid-Induced TNFR-Related Protein - metabolism
Biomarkers, Tumor - metabolism
B7 Antigens - metabolism
Adult - administration & dosage
Neoplasm Grading - administration & dosage
OX40 Ligand - metabolism
Prognosis - administration & dosage
Aged, 80 and over - administration & dosage

Find related publications in this database (Keywords)
Lung neuroendocrine neoplasm
Immunotherapy target
Immune phenotype
Immunohistochemistry
© Med Uni Graz Impressum